Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In this study, we evaluated acalabrutinib in spontaneously occurring canine lymphoma, a model of B-cell malignancy similar...

Full description

Bibliographic Details
Main Authors: Harrington, Bonnie K., Gardner, Heather L., Izumi, Raquel, Hamdy, Ahmed, Rothbaum, Wayne, Coombes, Kevin R., Covey, Todd, Kaptein, Allard, Gulrajani, Michael, Van Lith, Bart, Krejsa, Cecile, Coss, Christopher C., Russell, Duncan S., Zhang, Xiaoli, Urie, Bridget K., London, Cheryl A., Byrd, John C., Johnson, Amy J., Kisseberth, William C.
Format: Online
Language:English
Published: Public Library of Science 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951150/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951150/

Similar Items